NCT01842243

Brief Summary

Despite considerable effort the optimal site to place a pacemaker lead at the time of pacemaker implant remains unclear. Historically pacemaker leads have always been inserted at the bottom (apex) of the heart. It is suggested that a lead placed at the apex is associated with an increase in heart rhythm problems and also heart failure (impaired pumping function). The top of the ventricle (septum) has been investigated as an alternative site and is now routinely used by some centres. Previous estimation of the hearts pumping function (ejection fraction) has been limited to the use of echo (sound waves). Echo is not sensitive enough to detect small changes in the ejection fraction reliably (measure of pumping function of heart). The gold standard for measurement of ejection fraction is MRI (using magnets). Previous pacemakers have not been compatible with MRI scans. The latest generation of pacemakers are now able to be safely scanned within an MRI scanner. This allows a much more accurate estimation of the effects of a pacemaker on the ejection fraction which has not yet been studied. The investigators plan to study those patients undergoing a pacemaker implant and ablation procedure as part of their standard care. Individuals will have an exercise test, blood test used to measure biomarkers and fill in a symptom questionnaire. Individuals will have a Cardiac MR compatible pacemaker fitted and 2 ventricular leads will be inserted, one apically and one septally. Only one lead will be used at any given time. Individuals will then undergo their planned AV node ablation. Following this they will have a cardiac MR scan. Further MRI scans will be performed at 9 and 18 month intervals, as will symptom questionnaires, blood tests (BNP) to determine heart muscle strain, exercise testing and echocardiograms. The hypothesis is that a lead placed on the septum will produce superior cardiac performance over the short and long term.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
53

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Feb 2012

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2012

Completed
1.2 years until next milestone

First Submitted

Initial submission to the registry

April 24, 2013

Completed
5 days until next milestone

First Posted

Study publicly available on registry

April 29, 2013

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2015

Completed
Last Updated

February 4, 2019

Status Verified

January 1, 2013

Enrollment Period

3.9 years

First QC Date

April 24, 2013

Last Update Submit

February 1, 2019

Conditions

Keywords

Ventricular dysfunctionMRIEchocardiographyPacemakers

Outcome Measures

Primary Outcomes (1)

  • Ventricular Ejection fraction

    Comparison of % change in Left and Right Ventricular Ejection Fractions between apical and septal pacing groups as measured on MRI.

    18 months

Secondary Outcomes (12)

  • Levels of BNP

    18 months

  • MRI measures of Left and Right ventricular dyssynchrony

    18 months

  • Exercise Capacity as measured by CPEX

    18 months

  • 6 minute walk tests

    18 months

  • Quality of life measures SF36

    18 months

  • +7 more secondary outcomes

Study Arms (2)

Apical Pacing

ACTIVE COMPARATOR

Pacemaker programmed to pacing the heart at apex for 9 months.

Procedure: Apical pacingProcedure: Septal pacingDevice: Pacemaker

Septal Pacing

ACTIVE COMPARATOR

Pacemaker programmed to pacing the heart at the septum for 9 months.

Procedure: Apical pacingProcedure: Septal pacingDevice: Pacemaker

Interventions

Apical pacingPROCEDURE

Pacemaker set to pace at right ventricular apex initially.

Apical PacingSeptal Pacing
Septal pacingPROCEDURE

Pacemaker set to pace at right ventricular septum initially.

Apical PacingSeptal Pacing
PacemakerDEVICE

MR conditional Pacemaker implanted in all study patients

Also known as: MR conditional Pacemaker
Apical PacingSeptal Pacing

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients in permanent Atrial Fibrillation (AF)requiring a pacemaker on clinical grounds (tachycardia/bradycardia syndrome or requiring an AV node ablation)and AV node ablation or a pacemaker for rate control)
  • Patients aged 18 to 85 years old.
  • Able to consent for study.

You may not qualify if:

  • Patients with moderate to severe LV dysfunction (EF \< 40%).
  • Any contraindication to an MRI scan.
  • Patients indicated for an Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy.
  • Patients with a Myocardial Infarction within three months prior to enrollment.
  • Patients that received bypass surgery within three months prior to enrollment.
  • Patients that had a valve replacement within three months prior to enrollment or patients with a mechanical right heart valve.
  • Patients where a right ventricular lead cannot be placed e.g. complex congenital heart disease.
  • Patients with hypertrophic obstructive cardiomyopathy.
  • Patients with acute coronary syndrome, unstable angina, severe mitral regurgitation and/or haemodynamically significant aortic stenosis.
  • Previous implanted pacemaker or cardioverter defibrillator.
  • Terminal conditions with a life expectancy of less than two years.
  • Participation in any other study that would confound the results of this study.
  • Psychological or emotional problems that may interfere with the volunteer's ability to provide full consent or fully understand the purposes of the study.
  • Pregnant patients or patients who may become pregnant during the time-scale of the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital of South Manchester NHS trust

Manchester, M23 9LT, United Kingdom

Location

MeSH Terms

Conditions

Ventricular DysfunctionVentricular Remodeling

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular DiseasesPathological Conditions, AnatomicalPathological Conditions, Signs and Symptoms

Study Officials

  • Mark Dr Ainslie, MBChB

    University Hospital of South Manchester

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
DIAGNOSTIC
Intervention Model
CROSSOVER
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 24, 2013

First Posted

April 29, 2013

Study Start

February 1, 2012

Primary Completion

December 31, 2015

Study Completion

December 31, 2015

Last Updated

February 4, 2019

Record last verified: 2013-01

Locations